Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 60 Burkitt Lymphoma 10 Recurrence 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Large B-Cell, Diffuse 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Neoplasms, Plasma Cell 3 Lymphoma, Non-Hodgkin 3 Lymphoma, B-Cell 3 Lung Neoplasms 3 Leukemia, Biphenotypic, Acute 3 Carcinoma, Non-Small-Cell Lung 3 Waldenstrom Macroglobulinemia 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Immunoglobulin Light-chain Amyloidosis 2 Down Syndrome 2 Uterine Cervical Neoplasms 1 Smoldering Multiple Myeloma 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Prostate Cancer Metastatic 1 Plasmacytoma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasm Metastasis 1

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Dexamethasone × 30 days × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡